No results for ‘’
Kopran Ltd
₹203.13
(0.25%)
Wed, 29 Jul 2026, 04:29 am
Health Technology
Pharmaceuticals: Major
24.5KKopran Ratios
| Particulars | 2004 | 2005 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 21.36 | 11.17 | 4.61 | 4.85 | 0 | 18.92 | 16.51 | 11.64 | 7.49 | 5.22 | 7.37 | 20.44 | 19.55 | 24.45 | 21.91 |
| Price to book ratio | 3.05 | 1.65 | 1.05 | 0.45 | 1.63 | 1.28 | 0.77 | 0.58 | 0.79 | 2.08 | 2.12 | 2.63 | 1.65 | 1.07 | 0.58 | 1.85 | 3.19 | 1.21 | 2.54 | 1.63 |
| Price to sales ratio | 1.23 | 0.80 | 0.50 | 0.21 | 0.64 | 0.46 | 0.31 | 0.21 | 0.28 | 0.57 | 0.68 | 1.06 | 0.76 | 0.52 | 0.31 | 0.94 | 2.62 | 0.97 | 2.04 | 1.35 |
| Price to cash flow ratio | 0 | 0 | 8.70 | 44.56 | 0 | 8.32 | 2.37 | 16.21 | 0 | 5.40 | 12.40 | 122.90 | 13.17 | 10.74 | 4.93 | 8.40 | 0 | 17.96 | 35.63 | 25.65 |
| Enterprise value | 405Cr | 378Cr | 215Cr | 147Cr | 218Cr | 193Cr | 164Cr | 159Cr | 216Cr | 263Cr | 278Cr | 417Cr | 319Cr | 269Cr | 193Cr | 513Cr | 1265Cr | 595Cr | 1331Cr | 966Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 40.74 | 13.21 | 9.42 | 11.19 | 5.95 | 6.21 | 10.69 | 8.83 | 11.54 | 10.42 | 7.08 | 4.95 | 6.91 | 14.45 | 10.40 | 16.93 | 13.54 |
| Debt to equity ratio | 3.57 | 2.69 | 2.02 | 1.76 | 1.48 | 1.22 | 1.20 | 1.06 | 1.12 | 0.78 | 0.65 | 0.76 | 0.61 | 0.58 | 0.47 | 0.27 | 0.17 | 0.17 | 0.20 | 0.29 |
| Return on equity % | -36.43 | -12.08 | 0 | -20.20 | 0.21 | 5.85 | 6.41 | 12.14 | 16.22 | -36.72 | 10.34 | 17.06 | 14.73 | 15.34 | 11.74 | 28.34 | 18.19 | 6.29 | 10.95 | 7.64 |
Kopran Ltd Ratios
The Kopran Ltd Ratios page provides a complete fundamental analysis of Kopran Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Kopran Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Kopran Ltd (NSE: KOPRAN, BSE: 524280) is currently trading at ₹203.13, with a market capitalization of ₹966.2Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Kopran Ltd remains a key stock for fundamental analysis using Kopran Ltd Ratios.
Kopran Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Kopran Ltd P/E ratio currently stands at 21.91, making it one of the most tracked metrics in Kopran Ltd Ratios.
Historically, the Kopran Ltd P/E ratio has shown strong fluctuations:
- 2024: 21.91
- 2023: 24.45
- 2022: 19.55
- 2021: 20.44
- 2020: 7.37
The decline in Kopran Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Kopran Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.63.
Historical P/B trend:
- 2024: 1.63
- 2023: 2.54
- 2022: 1.21
- 2021: 3.19
Kopran Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Kopran Ltd P/S ratio currently stands at 1.35, an important part of Kopran Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 1.35
- 2023: 2.04
- 2022: 0.97
- 2021: 2.62
A stable or declining Kopran Ltd P/S ratio indicates cautious market sentiment.
Kopran Ltd Price to Cash Flow Ratio (P/CF)
The Kopran Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 25.65.
Historical Kopran Ltd Price to Cash Flow Ratio:
- 2024: 25.65
- 2023: 35.63
- 2022: 17.96
- 2021: 0
- 2020: 8.40
The declining Kopran Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Kopran Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Kopran Ltd EV currently stands at ₹966Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 966Cr
- 2023: 1331Cr
- 2022: 595Cr
- 2021: 1265Cr
Kopran Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Kopran Ltd EV/EBITDA ratio is currently 13.54, a key metric in Kopran Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 13.54
- 2023: 16.93
- 2022: 10.40
- 2021: 14.45
Stable Kopran Ltd EV/EBITDA indicates balanced valuation.
Kopran Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Kopran Ltd D/E ratio is currently 0.29, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.29
- 2023: 0.20
- 2022: 0.17
- 2021: 0.17
Kopran Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Kopran Ltd ROE currently stands at 7.64%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 7.64
- 2023: 10.95
- 2022: 6.29
- 2021: 18.19
Declining ROE indicates pressure on profitability.
Kopran Ltd Ratios Analysis Summary
The Kopran Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Kopran Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Kopran Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.